|
Age (yr)
|
|
< 50
|
359 (11.4)
|
124 (4.0)
|
483 (15.4)
|
|
50–69
|
976 (31.1)
|
508 (16.2)
|
1484 (47.3)
|
|
≥ 70
|
536 (17.1)
|
637 (20.3)
|
1173 (37.4)
|
|
Height (cm)a
|
168.7 ± 6.7
|
154.2 ± 6.1
|
162.7 ± 9.6
|
|
Body weight (kg)b
|
73.4 ± 12.5
|
60.8 ± 10.2
|
68.1 ± 13.2
|
|
Waist circumference (cm)c
|
90.0 ± 9.0
|
84.4 ± 9.6
|
87.7 ± 9.6
|
|
BMI (kg/m2)d
|
25.7 ± 3.5
|
25.5 ± 4.0
|
25.6 ± 3.8
|
|
Cardiocerebrovascular risk factors present
|
1825 (97.5)
|
1192 (93.9)
|
3017 (96.1)
|
|
Male ≥45 yr, female ≥55 yr
|
1643 (90.0)
|
1064 (89.3)
|
2707 (89.7)
|
|
Current smoker
|
451 (24.7)
|
21 (1.8)
|
472 (15.6)
|
|
BMI ≥25 kg/m2, or waist circumference > 90 cm (male) or > 80 cm (female)
|
673 (36.9)
|
455 (38.2)
|
1128 (37.4)
|
|
Dyslipidemia
|
911 (49.9)
|
613 (51.4)
|
1524 (50.5)
|
|
Impaired fasting glucose or impaired glucose tolerance
|
42 (2.3)
|
15 (1.3)
|
57 (1.9)
|
|
Family history of early cardiocerebrovascular disease (male, < 55 yr, female < 65 yr)
|
84 (4.6)
|
69 (5.8)
|
153 (5.1)
|
|
Diabetes mellitus
|
549 (30.1)
|
323 (27.1)
|
872 (28.9)
|
|
Medical history present
|
1667 (89.1)
|
1131 (89.1)
|
2798 (89.1)
|
|
Diseases of circulatory system
|
1234 (74.0)
|
773 (68.4)
|
2007 (71.7)
|
|
Endocrine, nutritional and metabolic diseases
|
1045 (62.7)
|
713 (63.0)
|
1758 (62.8)
|
|
Diseases of genitourinary system
|
276 (16.6)
|
123 (10.9)
|
399 (14.3)
|
|
Diseases of digestive system
|
138 (8.3)
|
140 (12.4)
|
278 (9.9)
|
|
Diseases of musculoskeletal system and connective tissue
|
98 (5.9)
|
111 (9.8)
|
209 (7.5)
|
|
Use of concomitant treatment with anti-hypertensives with nebivolol
|
1460 (78.0)
|
984 (77.5)
|
2444 (77.8)
|
|
Calcium antagonists
|
816 (55.9)
|
512 (52.0)
|
1328 (54.3)
|
|
Angiotensin II receptor antagonists
|
724 (49.6)
|
583 (59.3)
|
1307 (53.5)
|
|
Diuretics
|
299 (20.5)
|
279 (28.4)
|
578 (23.7)
|
|
ACE inhibitors
|
183 (12.5)
|
42 (4.3)
|
225 (9.2)
|
|
Alpha-blockers
|
24 (1.6)
|
9 (0.9)
|
33 (1.4)
|
|
Not available
|
10 (0.7)
|
2 (0.2)
|
12 (0.5)
|
